President Trump Imposes 100% Tariffs on Branded Pharmaceuticals

Key Takeaways

• 100% tariffs on non‑MFN patented drugs.
• EU, Japan, Korea, Switzerland, Liechtenstein face 15% duty.
• Onshoring agreements lower tariff to 20%.
• Orphan and animal health drugs exempt from tariffs.
• MFN pricing could delay U.S. drug launches.

Summary

President Trump has announced 100% tariffs on patented pharmaceutical products that lack a Most‑Favored Nation (MFN) agreement with his administration. The tariffs will take effect in 120 days for large firms and 180 days for smaller ones, while imports from the EU, Japan, Korea, Switzerland, Liechtenstein and, at a reduced rate, the UK will face only a 15% duty. Companies that secure MFN pricing or onshoring contracts avoid the full tariff, paying 0% until 2029 or a reduced 20% rate respectively. Exemptions include orphan drugs, animal‑health products and certain specialty items.

Pulse Analysis

The Trump administration’s 100% tariff on non‑MFN patented pharmaceuticals marks a dramatic escalation in trade policy aimed at bolstering domestic drug supply chains. By leveraging tariffs as a lever, the White House seeks to compel manufacturers to either secure MFN pricing—matching or beating the lowest international rates—or relocate production to the United States. The limited exemptions for major trading partners such as the EU and Japan, along with a modest 15% duty, reflect a strategic balance between protecting national interests and maintaining essential import relationships.

For pharmaceutical companies, the new tariff regime introduces a costly calculus. Firms without MFN agreements now face a full‑price duty that could double the landed cost of imported active ingredients, squeezing margins and prompting a reevaluation of launch sequencing. Analysts warn that the pressure to meet MFN pricing may delay U.S. market entries, as companies prioritize lower‑price reference markets to avoid eroding domestic profitability. The onshoring provision, offering a reduced 20% tariff, incentivizes domestic manufacturing but requires significant capital investment and supply‑chain restructuring, challenges that could slow innovation pipelines and raise drug prices for consumers.

The broader market impact extends beyond individual firms. Trade partners may view the selective 15% tariff as a signal of a more protectionist stance, potentially prompting retaliatory measures or renegotiations of existing agreements. Investors are likely to scrutinize companies’ exposure to imported APIs and their progress on MFN deals, influencing stock valuations. In this environment, proactive engagement with the administration, transparent pricing strategies, and accelerated domestic production initiatives will be critical for pharma leaders aiming to mitigate risk and sustain growth in a volatile regulatory landscape.